R&D channel feed – Endpoints News

R&D channel feed

First place finish: Eli Lilly just moved to franchise leader with their second migraine drug OK in 1 year

6 years ago

Court green-lights Clovis case after detailing evidence the board ‘ignored red flags’ on false safety and efficacy data

6 years ago

Long term data echo safety profile of Gilead, Galapagos' potential blockbuster JAK inhibitor

6 years ago

Researchers find 15% of trials could be replicated using real world data

6 years ago

Ex-AbbVie partner Principia posts encouraging PhII results for its BTK-inhibitor

6 years ago

J&J hands off non-opioid painkiller to an upstart in the race for next-gen analgesics

6 years ago

Bill Gates backs Ginkgo Bioworks' $350M raise to fuel the buzzy synthetic biology 'revolution'

6 years ago

Neglected on Wall Street, little Stealth Bio finds an affluent chum with $30M in cash and high hopes for their PhIII drug

6 years ago

Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators

6 years ago

Partner Bayer pushes Ionis' antithrombotic drug into mid-stage development

6 years ago

The new top 20 pharma list: Takeda jumps on, Biogen pushed out — and more big changes are on the way

6 years ago

A new player is taking the field in a push for a hemophilia A gene therapy, and it’s a big one

6 years ago

Rare disease clinical trials: FDA awards $15M in grants

6 years ago

Stuck with a PhIII gene therapy failure at 96 weeks, GenSight prefers the upbeat assessment

6 years ago

FDA approves drug for rare condition that triggers intense pain from light exposure

6 years ago

Drug price hikes, without justifiable new evidence of benefit — ICER analysis

6 years ago

Novartis nabs FDA approval for hyped Eylea rival

6 years ago

Novartis confidently breaks out mid-stage data on Xolair competitor

6 years ago

NGM Bio unveils positive PhII NASH results to some unimpressed investors

6 years ago

Acorda loses its last shot at protecting its cash cow franchise drug. It’s up to Inbrija now

6 years ago

Gilead chief O'Day recruits top Genentech researcher as new CMO in the wake of a high-level R&D exodus

6 years ago

Pfizer fronts $250M to nab antisense drug from Akcea/Ionis in up to $1.5B deal

6 years ago

New NIH viral vector flips the script on sickle cell disease gene therapy

6 years ago

Early functional data on limb girdle patients buoy expectations for Sarepta's gene therapy

6 years ago

First page Previous page 230 231 232233234 235 236 Next page Last page